BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Aug. 25, 2017

View Archived Issues

Australia's Invitrocue building personal tumor avatars to change personalized medicine

Read More

Drug, device industries keep fingers crossed as NAFTA II hammered out

Read More

What the drug and device industries want in NAFTA

Read More

Shanghai Ankon Tech raises $100M to push endoscopy pill in new markets, explore R&D

Read More

FDA says comparators still a part of post-approval studies

Read More

Appointments and advancements

Read More

Other news to note

Read More

Daily M&A

Read More

Financings

Read More

BioWorld Medtech's Diagnostics Extra

Read More

Profound set to bring in C$10M in offering to advance clinical trials for prostate treatment

Profound Medical Corp. is raising C$10 million (US$7.8 million) through a syndicate of underwriters led by Echelon Wealth Partners Inc., including CIBC Capital Markets. The Mississauga, Ontario-based company is offering an aggregate of 10,000,000 units at a price of C$1 (US80 cents) per unit. Each unit will consist of one common share of Profound (CVE:MRY.P) and one-half of one warrant, with each whole warrant enabling the holder to acquire one common share at a price of $1.40 (US$1.12) per share. Read More

Dexcom study supports CGM use in intensive T2 diabetes

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 11, 2025.
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing